The RNAseq of 79 small cell lung cancer (sclc) and 7 normal control

Even though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which predicts poor survival in Chinese SCLC patients. In vitro and in vivo studies have demonstrated that SRSF1 is essential for tumorigenecity of SCLC and plays a key role in DNA repair and chemo-sensitivity.

尽管小细胞肺癌（small cell lung cancer, SCLC）已迈入全基因组分析时代，但铂类化疗仍是SCLC的标准治疗方案。托泊替康是唯一获批用于复发或进展期SCLC的治疗药物[1]。在缺乏明确界定的基因组生物标志物的背景下，SCLC不同基因组亚型的临床疗效信号或已被漏检。丝氨酸/精氨酸剪接因子1（Serine/Arginine Splicing Factor 1, SRSF1）属于SR蛋白家族，其原癌基因过表达在人类癌症中所引发的不良后果表明，SRSF1介导的细胞转化存在复杂的机制与通路[2]。对99名中国患者的原发性SCLC肿瘤开展全外显子组测序与转录组测序后，发现SRSF1的DNA扩增与mRNA过表达可预测中国SCLC患者的不良预后。体外与体内研究均证实，SRSF1对SCLC的致瘤性至关重要，并在DNA修复与化疗敏感性中发挥关键作用。

搜集汇总

背景与挑战

背景概述

该数据集包含79个小细胞肺癌样本和7个正常对照样本的RNA测序数据，旨在研究SRSF1基因在肺癌中的作用及其对化疗敏感性的影响。数据使用Illumina HiSeq 2000平台生成，共包含86个样本的测序数据。